Thymic Hodgkin’s disease–a histological and immunohistochemical study of three cases.

Krugmann J, Feichtinger H, Greil R, Fend F. Pathol Res Pract. 1999,195(10):681-7.

Synergistic action of protein kinase C theta and calcineurin is sufficient for Fas ligand expression and induction of a crmA-sensitive apoptosis pathway in Jurkat T cells.

Villunger A, Ghaffari-Tabrizi N, Tinhofer I, Krumböck N, Bauer B, Schneider T, Kasibhatla S, Greil R, Baier-Bitterlich G, Uberall F, Green DR, Baier G. Eur J Immunol. 1999 Nov,29(11):3549-61.

Comparison of two quality-of-life instruments for cancer patients: the functional assessment of cancer therapy-general and the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30.

Kemmler G, Holzner B, Kopp M, DГјnser M, Margreiter R, Greil R, Sperner-Unterweger B. J Clin Oncol. 1999 Sep,17(9):2932-40.

Prognosis and management strategies of lymphatic neoplasias in the elderly. II. Hodgkin’s disease.

Greil R. Oncology. 1998 Jul-Aug,55(4):265-75.

Leg ulcers associated with long-term hydroxyurea therapy.

Weinlich G, Schuler G, Greil R, Kofler H, Fritsch P. J Am Acad Dermatol. 1998 Aug,39(2 Pt 2):372-4.

Interferon-alpha for the treatment of elderly patients with chronic myeloid leukaemia.

Hilbe W, Apfelbeck U, Fridrik M, Bernhart M, Niessner H, Abbrederis K, Michlmayr G, Pont J, Linkesch W, Hausmaninger H, Arneitz K, Baldinger C, Duba C, Eisterer W, Greil R, Konwalinka G, Niederwieser D, Gastl G, Thaler J. Leuk Res. 1998 Oct,22(10):881-6.

Vinorelbine/gemcitabine in advanced non-small cell lung cancer (NSCLC): a phase I trial.

Krajnik G, Wein W, Greil R, Marhold F, Mohn-Staudner A, Kummer F, Malayeri R, Zöchbauer-Müller S, Huber H, Pirker R. Eur J Cancer. 1998 Nov,34(12):1977-80.

Inversion of CD4(+)/CD8(+) ratio in B chronic lymphocytic leukemia correlates with differential sensitivity of CD4(+) and CD8(+) T lymphocytes to the killing efficacy of Fas (APO-1/CD95) ligand(+) tumor cells.

Tinhofer, I, Marschitz, I, Kos, M, Henn, T, Egle, A, Villunger, A, Greil, R BLOOD. 1998, 92(10): 271B-271B.

Differential sensitivity of CD4+ and CD8+ T lymphocytes to the killing efficacy of Fas (Apo-1/CD95) ligand+ tumor cells in B chronic lymphocytic leukemia.

Tinhofer I, Marschitz I, Kos M, Henn T, Egle A, Villunger A, Greil R. Blood. 1998 Jun 1,91(11):4273-81.

Functional granulocyte/macrophage colony stimulating factor receptor is constitutively expressed on neoplastic plasma cells and mediates tumour cell longevity.

Villunger A, Egle A, Kos M, Egle D, Tinhofer I, Henn T, Uberall F, Maly K, Greil R. Br J Haematol. 1998 Sep,102(4):1069-80.